Literatura académica sobre el tema "Risque thrombotique"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Risque thrombotique".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Risque thrombotique"
Merdji, Hamid, Laurent Sattler, Sibylle Cunat, Ferhat Meziani y Julie Helms. "Hémostase et COVID-19". Médecine Intensive Réanimation 30, Hors-série 1 (16 de junio de 2021): 35–42. http://dx.doi.org/10.37051/mir-00062.
Texto completoCasadevall, N. y M. M. Samama. "Risque thrombotique des syndromes myéloprolifératifs". Journal des Maladies Vasculaires 33 (marzo de 2008): S27—S28. http://dx.doi.org/10.1016/j.jmv.2008.01.091.
Texto completoCatteau-Jonard, S. "Risque thrombotique des nouvelles contraceptions". Journal des Maladies Vasculaires 36, n.º 5 (septiembre de 2011): 306–7. http://dx.doi.org/10.1016/j.jmv.2011.07.059.
Texto completoÉmile, Carole. "Risque thrombotique de la Covid-19". Option/Bio 32, n.º 629-630 (marzo de 2021): 20–21. http://dx.doi.org/10.1016/s0992-5945(21)00048-9.
Texto completoTrillot, N., V. Tintillier, B. Jude, C. Biron-Andréani, P. E. Morange y S. Susen. "Risque thrombotique veineux de la femme jeune". Journal des Maladies Vasculaires 40, n.º 2 (marzo de 2015): 77–78. http://dx.doi.org/10.1016/j.jmv.2014.12.077.
Texto completoAiach, Martine. "Risque thrombotique veineux, grossesse et traitement ȩstroprogestatif". Revue Française des Laboratoires 2003, n.º 349 (enero de 2003): 11–13. http://dx.doi.org/10.1016/s0338-9898(03)80043-4.
Texto completoBelizna, C. y A. Ghali. "Titres des anticorps anticardiolipine et risque thrombotique". La Revue de Médecine Interne 35 (junio de 2014): A60. http://dx.doi.org/10.1016/j.revmed.2014.03.067.
Texto completoGodier, Anne y Sophie Susen. "Risque thrombotique des traitements médicamenteux des hémorragies". Anesthésie & Réanimation 1, n.º 3 (junio de 2015): 248–55. http://dx.doi.org/10.1016/j.anrea.2014.12.013.
Texto completoGuy, Alexandre y Chloé James. "La thrombose au cours des néoplasies myéloprolifératives". médecine/sciences 35, n.º 8-9 (agosto de 2019): 651–58. http://dx.doi.org/10.1051/medsci/2019133.
Texto completoKeïta-Meyer, H. "Risque thrombotique dans le postpartum : facteurs de risque généraux et obstétricaux". Journal des Maladies Vasculaires 37, n.º 2 (marzo de 2012): 48–49. http://dx.doi.org/10.1016/j.jmv.2011.12.088.
Texto completoTesis sobre el tema "Risque thrombotique"
Collet, Jean-Philippe. "Anomalie qualitative du fibrinogène, facteur de risque thrombotique ?" Rouen, 1996. http://www.theses.fr/1996ROUE03NR.
Texto completoJesel-Morel, Laurence. "Sénescence, remodelage tissulaire et membranaire, risque thrombotique au cours de la fibrillation auriculaire". Thesis, Strasbourg, 2016. http://www.theses.fr/2016STRAJ051/document.
Texto completoOur data evidence that during atrial fibrillation (AF), microparticles (MP) contribute to an enhanced hypercoagulable and pro-inflammatory state. Similar concentrations of MP measured in left and right atria of AF patients highlight the absence of chamber-specific enhanced thrombogenic status. During AF ablation procedures, MP concentrations progress in parallel with cell and platelet activation. We also showed that AF progression is strongly related to human atrial senescence burden pointing toward a possible network that links in human atrium, senescence burden, endothelial dysfunction, thrombogenicity and atrial remodeling. We also developed a model of left atrium endothelial cell replicative senescence providing compelling evidences indicating that atrial endothelial senescence promotes thrombogenicity, inflammation and proteolysis. These data underline the major role of renin-angiotensin system in endothelial atrial cell senescence
Bene, Johana. "Déterminants du risque hémorragique et thrombotique des anticoagulants oraux et études de bon usage". Thesis, Lille 2, 2016. http://www.theses.fr/2016LIL2S012/document.
Texto completoFor over six decades, vitamin K antagonists (VKAs) were the only class of oral anticoagulants available on the market. The arrival of Direct Oral Anticoagulants (DOAs) in 2008 marked a real turning point in the oral anticoagulation. The first part of this work was interested in the characteristics of patients treated with anticoagulants and the consequences in terms of hospitalizations for ischemic or hemorrhagic events. In a cohort of patients hospitalized for stroke (cohort BIOSTROKE Lille), no particular influencer, on the onset and course (mortality, cognitive decline, and disability at 3 months) of stroke was highlighted. In parallel, a study conducted in the emergency department of the Hospital of Bethune on three years (2012, 2014, 2016) to observe oral anticoagulants prescriptions and the impact of DOAs arriving, showed a population where many characteristics appear to be associated with a more readily using DOAs or VKAs. The number of bleeding and thrombotic events with VKAs remained stable during the three study periods (in total 770 patients were included). With these reassuring data, the second part of this work has focused on prescribing practices and the appropriate use of anticoagulants, with a particular focus on DOAs, through three studies: one conducted among general practitioners of Nord and Pas de Calais departments, which showed a rather wary about DOAs but with a preference for anti-Xa. The other two studies focused on the appropriate use of DOAs, estimated from pharmacy (with the participation of pharmacy students of the Faculty of Lille) and hospital (Lille Regional Hospital Center) prescriptions. Data about DOAs prescriptions were transposable to French data, albeit with city / hospital disparities. Non-appropriate prescriptions were observed in less than one-third file, with a high proportion of under dosing situations. In conclusion, this work has allowed updating training tracks / information for health care professionals on these new anticoagulant molecules to improve information and optimal patients’ care
Le, Flem Léna. "Etude du promoteur du gène de la thrombomoduline dans la maladie thrombotique veineuse". Paris 5, 1997. http://www.theses.fr/1997PA05P031.
Texto completoZuily, Stéphane. "Proposition de nouveaux critères cliniques et biologiques dans l'évaluation du risque thrombotique des patients atteints de syndrome des antiphospholipides". Thesis, Université de Lorraine, 2014. http://www.theses.fr/2014LORR0064.
Texto completoAntiphospholipid syndrome (APS) is characterized by an auto-immune disorder with thrombotic and obstetrical morbidity in the presence of persistant antiphospholipid antibodies (aPL). This work studied clinical manifestations and laboratory assays for the determination of thrombotic risk in APS patients. Firstly, the risk of heart valve disease associated with aPL in systemic lupus erythematosus (SLE) patients was studied. Since 20 years, data regarding this association yielded conflicting results. A systematic review and a meta-analysis were performed to compare frequencies of heart valve disease in SLE patients with and without aPL. Main result concluded that the presence of aPL in SLE patients is associated with a 3-fold increased risk for heart valve disease in comparison with SLE patients without these antibodies. Secondly, prognostic significance of superficial vein thrombosis (SVT) was studied in APS patients. A prospective cohort study was performed and showed that SVT was predictive of thrombotic events overtime in this population. Moreover, the contribution of new laboratory assays were studied (antibodies directed against the domain I of [beta]2-Glycoprotein I and thrombin generation assay assessing sensitivity to activated protein C). Results demonstrated that these two assays were predictive of thrombotic events in APS patients. Finally, health-related quality of life was assessed in a multicentric cohort study of patients with aPL and/or SLE. Results showed that the presence of a history of arterial thrombosis was significantly associated with an impairment of all dimensions scores assessed by the MOS-SF36 questionnaire in comparison with patients with an auto-immune disease but without arterial thrombosis. This work provides new insights in the field of APS and may have an impact in the evolution leading to new classification criteria for definite APS
Aubert, Hélène. "Mise en évidence du déterminisme génétique du taux plasmatique de TAFI : Etude de la contribution du TAFI au risque thrombotique artériel". Aix-Marseille 2, 2003. http://www.theses.fr/2003AIX22063.
Texto completoLabbé, Vincent. "Risques thrombotiques et hémodynamiques chez les patients hospitalisés en réanimation présentant une fibrillation atriale de novo au cours d’un sepsis : caractérisation, stratification et stratégies thérapeutiques". Electronic Thesis or Diss., Sorbonne université, 2023. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2023SORUS556.pdf.
Texto completoObjectives Patients admitted to intensive care units with sepsis are at high risk of thrombotic events (TEs) throughout the circulatory systems (systemic, coronary, and pulmonary). We aimed to investigate the thrombotic risk during sepsis (i) within the systemic circulation in patients with new-onset atrial fibrillation (NOAF), (ii) within the coronary circulation in patients with acute myocardial infarction (MI), and (iii) within the pulmonary circulation in patients with severe COVID-19. Furthermore, while the risk of TE raises the question of whether thromboprophylaxis doses should be escalated, assessment of associated bleeding risk should be systematic in order to establish the benefit/risk balance of such treatment. Methods We investigated the risk of major cardiovascular events (risk characterization and stratification), including AT, major bleeding and death in three populations of septic patients with NOAF, MI or severe COVID-19 by studying (i) markers such as left atrial dysfunction on transesophageal echocardiography (TEE) and cardiac troponin, and (ii) thrombotic and hemorrhagic risk scores used in cardiology patients. We conducted a practice survey on thrombotic risk management in patients with de NOAF during sepsis. Finally, we carried out two therapeutic trials: the CAFS (Control Atrial Fibrillation Sepsis) multicenter, randomized, controlled superiority trial comparing three usual strategies to prevent hemodynamic risk with NOAF during septic shock (currently being included), and the ANTICOVID (ANTIcoagulation in patients with hypoxemic COVID-19 pneumonia) multicenter, randomized, controlled superiority trial comparing three anticoagulation strategies with dose escalation in patients with hypoxemic COVID-19 pneumonia Results Our work confirmed the high risk of major cardiovascular events during sepsis. In patients with NOAF, cardiological approaches to thrombotic (TEE abnormalities, CHA2DS2-VASc score) and hemorrhagic (HAS-BLED score) risk stratification seem limited. An individualized approach with TEE based on the CHA2DS2-VASc score could nevertheless be of interest. This work also better characterized the risk of intra-cardiac thrombus formation (absence of thrombus within 48 h of AF onset, low prevalence of post-cardioversion left atrial stunning). Finally, we confirmed the heterogeneity of hemodynamic and thrombotic risks management, calling for randomized trials. In patients with MI during sepsis, cardiological approaches to thrombotic risk stratification (GRACE and TIMI scores) also appear limited. In usual practice, an invasive strategy involving early coronary revascularization is very uncommon. In patients investigated using coronary angiography, the incidence of obstructive coronary artery disease is high. In patients with hypoxemic COVID-19 pneumonia, high-dose prophylactic anticoagulation, provided a better net clinical benefit driven by a 4-fold reduction in de novo thrombosis rate with no increase in major bleeding compared with standard-dose prophylactic anticoagulation. Also, therapeutic anticoagulation did not provide additional benefit in comparison with high-dose prophylactic anticoagulation. Conclusions On the basis of the common pro-thrombotic pathophysiology described in septic conditions, our work has made it possible to (i) better characterize clinical situations at particularly high thrombotic risk (NOAF, MI, severe COVID-19 infection), (ii) develop individual therapeutic strategies for thrombotic risk prevention (COVID-19), and (iii) establish the basis for subsequent trials in specific intensive care populations at very high thrombotic risk
Chauleur, Céline. "Identification des facteurs de risque pour prévenir les complications thrombotiques et hémorragiques de la grossesse". Saint-Etienne, 2009. http://www.theses.fr/2009STET003T.
Texto completoCapítulos de libros sobre el tema "Risque thrombotique"
Odent, T., B. de Courtivron y Y. Gruel. "Risque thrombotique et chirurgie orthopédique chez l'enfant". En Conférences D'enseignement 2019, 155–62. Elsevier, 2019. http://dx.doi.org/10.1016/b978-2-294-76675-6.00014-7.
Texto completo